This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novozymes-Chr. Hansen merger decision shows EU’s focus on innovation

By Andrew Boyce ( November 28, 2024, 14:46 GMT | Comment) -- EU regulators are under pressure to give more leeway to companies to merge to gain scale, which would allow them to innovate. But a decision published this week on Novozymes’ merger with Chr. Hansen showed how the European Commission looked hard at whether creating a large European player in enzymes would actually be bad for innovation more broadly, by making it hard for rivals to keep up with its R&D spending.A newly published decision on Novozymes’ merger with Chr. Hansen showcases the knotty balancing act at the heart of an EU debate on whether competition regulators should allow European companies to merge to boost innovation....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login